Search

Your search keyword '"Atmaca, Murat"' showing total 212 results
Start Over Author "Atmaca, Murat"
212 results on '"Atmaca, Murat"'

1. Associations between stages of diabetic polyneuropathy and quality of life, neuropathic pain, and well-being: A multicenter, cross-sectional analysis based on electroneuromyographic findings

Author

Cengiz, Emine Kılıçparlar, Fırat, Yasemin Ekmekyapar, Karşıdağ, Sibel, Neyal, Abdurrahman, Erdemoğlu, Ali Kemal, Çınar, Nilgün, Ekmekyapar, Tuba, Kabay, Sibel Canbaz, Arıkan, Fatma Akkoyun, Akdağ, Gönül, Çomruk, Gülsüm, Ateş, Miruna, Aslan, Sude Kendirli, Çokal, Burcu Gökçe, Tosunoğlu, Bünyamin, Bolu, Naci Emre, Yanık, Ece, Savrun, Feray, Tülek, Zeliha, Kılıçaslan, Kimya, Çakar, Egemen Kaan, Bakar, Ebru Ergin, Atmaca, Murat Mert, Yılmaz, Buket, and Neyal, Ayşe Münife

Published
2025
Full Text
View/download PDF

2. The effect of sleep disorders on quality of life in patients with epilepsy: A multicenter study from Turkey

Author

Akdağ, Gönül, Canbaz Kabay, Sibel, Bican Demir, Aylin, Ergin Bakar, Ebru, Koç, Güray, Üstün Özek, Sibel, Küçük, Ahmet, Ünsal, Miraç Ayşen, Neyal, Abdurrahman, Florentina Ateş, Miruna, Çelik, Havva Tuğba, Kılıçparlar Cengiz, Emine, Kutlu, Gülnihal, Ağırcan, Dilek, Karacan Gölen, Meltem, Bek, Semai, Çınar, Nilgün, Sahin, Sevki, Şişman Bayar, Aysel Büşra, Terzi, Murat, Kendirli Aslan, Sude, Kenar, Safiye Gül, Kutluhan, Süleyman, Ekmekyapar Fırat, Yasemin, Yılmaz Okuyan, Dilek, Bayar, Muhammet Duran, Mert Atmaca, Murat, Yalçın, Destina, Genç, Fatma, Köse Leba, Leyla, Yılmaz, Buket, Eren, Fettah, Bolu, Naci Emre, Keskin Güler, Selda, Akıncı, Tuba, Reyhani, Aylin, Yıldırım Sitembölükbaşı, Neslişah, Türkmen, Nur, Karşıdağ, Sibel, Velioğlu, Sibel K., Demir, Ayşegül, Haytı, Barış, Hasırcı Bayır, Buse Rahime, Ezgi Uçan Tokuç, Firdevs, Demir, Göksemin, Çakmakçı, Güngör, Özkan, Hülya, Bulut, Onur, Kesim Şahin, Özlem, Sürmeli, Reyhan, Tekin, Selma, Sarıoğlu, Şerife Gizem, Gesoğlu Demir, Tülin, Akkoyun Arıkan, Fatma, and Çetiner, Mustafa

Published
2024
Full Text
View/download PDF

4. Autoimmune encephalitis and paraneoplastic syndromes in Turkey: a multi-centre study

Author

Gozubatik-Celik, Rabia Gokcen, Gul, Zeynep Bastug, Bilgin, Elif Bengisu, Yildiz, Mina Uzulmez, Yenidunya, Onur, Misirli, Handan, Celik, Havva Tugba, Kurtulus, Fatma, Yaman, Aylin, Domac, Fusun, Karaci, Rahsan, Cokar, Ozlem, Culha Oktar, Ayla, Emre Toprak, Ufuk, Yavuz, Nurettin, Dalgıc, Elif, Ozen Barut, Banu, Dogan Ak, Pelin, Ozgenc, Cisil Irem, Bulbul, Nazlı Gamze, Atmaca, Murat Mert, Gokyigit, F. Munevver, Gürkan, Zahide Mail, Pazarci, Nevin, Surmeli, Reyhan, Kale, Nilufer, Yildirim, Zerrin, Yayla, Vildan, Sozer, Necla, Cabalar, Murat, Delen, Firuze, Ucler, Serap, Unal, Elif, Sungur, M. Ali, Sen, Aysu, Atakli, Dilek, and Soysal, Aysun

Published
2022
Full Text
View/download PDF

5. Incidence and Features of Acute Ischemic Stroke in Patients Hospitalized with COVID-19: A Multi-center Study in Turkey.

Author

Atmaca, Murat Mert, Bülbül, Nazlı Gamze, Ateş, Miruna Florentina, Selbest, Burcu, Eren, Fettah, Güler, Sibel, Şimşek1, Uğur Burak, Yetkin, Mehmet Fatih, Akcakoyunlu, Merve, Biçer, Elif Özge, Kılıç, Soner, Yetkin, Nur Aleyna, Taş, Şazimet, Kocakaya, Zeynep, Karasu, Kevser, Yüksel, Ufuk, Kılıç, Ayşegül Ulu, Yüce, Zeynep Türe, Tutar, Nuri, and Ketencioğlu, Burcu Baran

Subjects
*MYOCARDIAL infarction risk factors, *HYPERTENSION risk factors, *HEART failure risk factors, *CROSS-sectional method, *NIH Stroke Scale, *HOSPITAL care, *TREATMENT effectiveness, *SEVERITY of illness index, *HOSPITAL mortality, *AGE distribution, *ISCHEMIC stroke, *RESEARCH, *INTENSIVE care units, *STROKE, *CORONARY artery disease, *LENGTH of stay in hospitals, *COVID-19, *BIOMARKERS, *DISEASE risk factors, *SYMPTOMS
Abstract

Introduction: Acute ischemic stroke (AIS) is a devastating complication of COVID-19 with high morbidity and mortality. In this study, we reported the frequency, characteristics, and outcome of AIS in patients with COVID-19. Methods: This multicenter and cross-sectional study was conducted between April 2020 and February 2021. Among the hospitalized patients with COVID-19, the detailed characteristics of those with and without AIS were recorded and compared. Results: Six hundred ninety-three patients were included in the study. Acute ischemic stroke was detected in 16 (2.31%) patients, the median age was 77 (range, 48-91) years, and 10 (62.5%) were female. The median NIHSS score at admission was 9 (range, 3-17). Total anterior circulation infarction (TACI) was the most common (37.5%) type and cardioembolism was the most common etiology (37.5%). Nine patients (56.25%) developed AIS within 24 hours of having COVID-19. COVID-19 severity was severe or critical in seven patients (43.75%). Eight patients died, and eight were discharged. Patients with AIS had a higher rate of hypertension, coronary artery disease, heart failure, a history of myocardial infarction, a history of cerebrovascular disease, severe and critical COVID-19, a higher mean age, and a longer ICU stay compared with those without AIS (p<0.001 for each). Conclusions: AIS can occur in patients with COVID-19 and is associated with mortality. Acute ischemic stroke is encountered at any stage of COVID-19, especially within the first 72 hours of the diagnosis, in older patients with comorbidities and severe COVID-19. There is an increased risk of AIS in patients with COVID-19 with a history of stroke. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Neurological Manifestations and Comorbidities in Coronavirus Disease 2019 (COVID-19) Patients: Multicenter Study.

Author

Bülbül, Nazlı Gamze, Atmaca, Murat Mert, Karşıdağ, Sibel, Ateş, Miruna Florentina, Selbest, Burcu, Eren, Fettah, Güler, Sibel, Şimşek, Uğur Burak, Yetkin, Mehmet Fatih, Akçakoyunlu, Merve, Biçer, Elif Özge, Kılıç, Soner, Taş, Şazimet, Kocakaya, Zeynep, Karasu, Kevser, Yüksel, Ufuk, Kılıç, Ayşegül Ulu, Türe, Zeynep, Tutar, Nuri, and Ketencioğlu, Burcu Baran

Subjects
*SARS-CoV-2, *COVID-19, *TASTE disorders, *CORONAVIRUS diseases, *NEUROLOGIC manifestations of general diseases, *COVID-19 pandemic, *NEUROLOGICAL disorders
Abstract

Objective: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, responsible for the Coronavirus Disease 2019 (COVID-19) pandemic, originated in China and swiftly spread globally, resulting in significant mortality worldwide. We aimed to create an overview of the significant symptoms, clinical indicators, and concurrent comorbidities observed in COVID-19 patients that require hospitalization and neurology consultation, adversely affecting the severe course of the disease and leading to mortality. Materials and Methods: We designed our study as a multicenter and cross-sectional survey, which was conducted with patients hospitalized in seven medical centers in Türkiye over six months. Results: A cohort of 504 patients diagnosed with COVID-19 were included in the study. In terms of the complaints at the time of admission, high fever (48%), cough (45%), sore throat (23%), and diarrhea (9%) were the most common symptoms expressed by the patients. The most commonly observed symptoms included myalgia (55%), headache (46%), loss of taste (46%), and loss of smell (39%). Furthermore, 68 patients (13.5%) within the cohort had a history of neurological diseases, distributed as follows: cerebrovascular attack (4%), migraine (2.8%), extrapyramidal disease (1.8%), dementia (1%), polyneuropathy (1%), epilepsy (0.6%), and demyelinating disease (0.6%). In the logistic regression analysis, key factors affecting mortality were identified as body mass index and age. Conclusion: The most common complaints in COVID-19 patients were high fever and sore throat. Fatigue, myalgia, headache, loss of smell, and taste were the most common symptoms. Accompanying comorbid diseases increased the severity of COVID-19 disease. Advanced age and body mass index were effective factors on mortality. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Acute Stroke Management in Türkiye: Intravenous Tissue Plasminogen Activator and Thrombectomy NöroTek: Türkiye Neurology Single Day Study

Author

Topçuoğlu, Mehmet Akif, primary, Özdemir, Atilla Özcan, additional, Arsava, Ethem Murat, additional, Güneş, Aygül, additional, Aykaç, Özlem, additional, Sarıönder Gencer, Elif, additional, Çabalar, Murat, additional, Yayla, Vildan, additional, Erdoğan, Hacı Ali, additional, Erdoğan, Mücahid, additional, Özdemir Acar, Zeynep, additional, Giray, Semih, additional, Kablan, Yüksel, additional, Tanrıverdi, Zeynep, additional, Yalaz Tekan, Ülgen, additional, Asil, Talip, additional, Akpınar, Çetin Kürşad, additional, Yürekli, Vedat Ali, additional, Acar, Bilgehan, additional, Şirin, Hadiye, additional, Güler, Ayşe, additional, Baydemir, Recep, additional, Akçakoyunlu, Merve, additional, Öcek, Levent, additional, Çetiner, Mustafa, additional, Nazlıel, Bijen, additional, Çağlayan, Hale Batur, additional, Ongun, Nedim, additional, Eren, Alper, additional, Arlıer, Zülfikar, additional, Cenikli, Utku, additional, Gökçe, Mustafa, additional, Bavli, Songül, additional, Yaka, Erdem, additional, Özkul, Ayça, additional, Değirmenci, Bahar, additional, Aluçlu, Ufuk, additional, Togay Işıkay, Canan, additional, Aslanbaba, Eda, additional, Sorgun, Mine, additional, Aytaç, Emrah, additional, Ay, Halil, additional, Kunt, Refik, additional, Şenadım, Songül, additional, Özüm Ünsal, Yaprak, additional, Eşkut, Neslihan, additional, Alioğlu, Zekeriya, additional, Yılmaz, Arda, additional, Genç, Hamit, additional, Yılmaz, Ayşe, additional, Milanoğlu, Aysel, additional, Gürkaş, Erdem, additional, Değirmenci, Eylem, additional, Bektaş, Hesna, additional, İlgezdi, İrem, additional, Bilgiç, Adnan Burak, additional, Akyol, Şenol, additional, Güngör, Levent, additional, Kale, Nilüfer, additional, Çoban, Eda, additional, Yeşilot, Nilüfer, additional, Ekizoğlu, Esme, additional, Kizek, Özgü, additional, Kurşun, Oğuzhan, additional, Kayım Yıldız, Özlem, additional, Bolayır, Aslı, additional, Kısabay, Aysın, additional, Baştan, Birgül, additional, Acar, Zeynep, additional, Niflioğlu, Buket, additional, Güven, Bülent, additional, Kaya, Dilaver, additional, Afşar, Nazire, additional, Yazıcı, Duran, additional, Toplutaş, Eren, additional, Özkan, Esra, additional, İlik, Faik, additional, İnce, Fatma Birsen, additional, Büyükşerbetçi, Gülseren, additional, Önder, Halil, additional, Karadeli, Hasan Hüseyin, additional, Kozak, Hasan Hüseyin, additional, Demirbaş, Hayri, additional, Midi, İpek, additional, Aydın, İsa, additional, Epçeliden, M. Tuncay, additional, Atmaca, Murat Mert, additional, Bakar, Mustafa, additional, Şen, Mustafa, additional, Turgut, Nilda, additional, Keskin, Onur, additional, Akdoğan, Özlem, additional, Emre, Ufuk, additional, Bilgili, Özlem, additional, Bekdik Şirinocak, Pınar, additional, Yevgi, Recep, additional, Yazıcı Akkaş, Sinem, additional, Yoldaş, Tahir, additional, Duman, Taşkın, additional, Özel, Tuğba, additional, Ünal, Ali, additional, Dora, Babür, additional, Atasoy, Tuğrul, additional, Piri Çınar, Bilge, additional, Demir, Tülin, additional, Demir, Turgay, additional, Can, Ufuk, additional, Aslan, Yıldız, additional, Baş, Demet Funda, additional, Şener, Ufuk, additional, Yılmaz, Zahide, additional, Bozdoğan, Zehra, additional, Özdemir, Gökhan, additional, Krespi, Yakup, additional, and Öztürk, Şerefnur, additional

Published
2023
Full Text
View/download PDF

12. Reconsidering the Relationship Between Hand Preference and Cerebral Vascular Dominance: A Computed Tomography (CT) Angiography Study

Author

Bulbul, Nazli, Demir, Serkan, Özkan, Suat, Samanci, Cesur, Atmaca, Murat, Çelik, Didem, Köse, Ercan, Alparslan, Funda, Altiner, Aysenur, Ari, Selma, Dogan, Ceyda, Yavuz, Cansu, Arslan, Zeynep, Aksahin, Okan, and Özdag, Mehmet

Subjects
Brain research, Left- and right-handedness -- Research, Angiography -- Usage, CT imaging -- Usage, Cerebral dominance -- Psychological aspects -- Physiological aspects, Health
Abstract

Byline: Nazli. Bulbul, Serkan. Demir, Suat. Özkan, Cesur. Samanci, Murat. Atmaca, Didem. Çelik, Ercan. Köse, Funda. Alparslan, Aysenur. Altiner, Selma. Ari, Ceyda. Dogan, Cansu. Yavuz, Zeynep. Arslan, Okan. Aksahin, Mehmet. [...]

Published
2022

13. Atrial Fibrillation Management in Acute Stroke Patients in Türkiye: Real-life Data from the NöroTek Study

Author

Topçuoğlu, Mehmet Akif, primary, Arsava, Ethem Murat, additional, Özdemir, Atilla Özcan, additional, Aykaç, Özlem, additional, Çetiner, Mustafa, additional, Sarıönder Gencer, Elif, additional, Güneş, Aygül, additional, Krespi, Yakup, additional, Yaka, Erdem, additional, Öcek, Levent, additional, Tanrıverdi, Zeynep, additional, Yalaz Tekan, Ülgen, additional, Özkul, Ayça, additional, Özkan, Esra, additional, Şirin, Hadiye, additional, Güler, Ayşe, additional, Kurşun, Oğuzhan, additional, Kunt, Refik, additional, Cenikli, Utku, additional, Acar, Bilgehan, additional, Kablan, Yüksel, additional, Yılmaz, Ayşe, additional, Işıkay, Canan Togay, additional, Aslanbaba, Eda, additional, Sorgun, Mine, additional, Bektaş, Hesna, additional, Çabalar, Murat, additional, Yayla, Vildan, additional, Erdoğan, Hacı Ali, additional, Gökçe, Mustafa, additional, Bavli, Songül, additional, Ongun, Nedim, additional, Keskin, Ahmet Onur, additional, Akdoğan, Özlem, additional, Emre, Ufuk, additional, Kayım Yıldız, Özlem, additional, Bolayır, Aslı, additional, Akpınar, Çetin Kürşad, additional, Karadeli, Hasan Hüseyin, additional, Özel, Tuğba, additional, Ünal, Ali, additional, Dora, Babür, additional, Arlıer, Zülfikar, additional, Eren, Alper, additional, Milanoğlu, Aysel, additional, Nazliel, Bijen, additional, Batur Çağlayan, Hale, additional, Güven, Bülent, additional, Erdoğan, Mücahid, additional, Özdemir Acar, Zeynep, additional, Bakar, Mustafa, additional, Giray, Semih, additional, Şenadım, Songül, additional, Asil, Talip, additional, Demir, Turgay, additional, Özüm Ünsal, Yaprak, additional, Eşkut, Neslihan, additional, Baştan, Birgül, additional, Acar, Zeynep, additional, Niflioğlu, Buket, additional, Yazıcı, Duran, additional, Aytaç, Emrah, additional, İnce, Fatma Birsen, additional, Ay, Halil, additional, Önder, Halil, additional, Kozak, Hasan Hüseyin, additional, İlgezdi, İrem, additional, Bilgiç, Adnan Burak, additional, Akyol, Şenol, additional, Güngör, Levent, additional, Atmaca, Murat Mert, additional, Şen, Mustafa, additional, Yevgi, Recep, additional, Yazıcı Akkaş, Sinem, additional, Yoldaş, Tahir, additional, Atasoy, H. Tuğrul, additional, Çınar, Bilge Piri, additional, Yılmaz, Arda, additional, Genç, Hamit, additional, Kısabay, Ayşın, additional, İlik, Faik, additional, Demirbaş, Hayri, additional, Midi, İpek, additional, Bekdik Şirinocak, Pınar, additional, Duman, Taşkın, additional, Demir, Tülin, additional, Can, Ufuk, additional, Yürekli, Vedat Ali, additional, Bozdoğan, Zehra, additional, Alioğlu, Zekeriya, additional, Kaya, Dilaver, additional, Afşar, Nazire, additional, Gürkaş, Erdem, additional, Toplutaş, Eren, additional, Değirmenci, Eylem, additional, Büyükşerbetçi, Gülseren, additional, Aydın, İsa, additional, Epçeliden, M. Tuncay, additional, Turgut, Nilda, additional, Kale, Nilüfer, additional, Çoban, Eda, additional, Yeşilot, Nilüfer, additional, Ekizoğlu, Esme, additional, Kizek, Özgü, additional, Bilgili, Özlem, additional, Baydemir, Recep, additional, Akçakoyunlu, Merve, additional, Yılmaz, Zahide, additional, and Öztürk, Şerefnur, additional

Published
2023
Full Text
View/download PDF

15. CHADS[sub]2 and CHA[sub]2DS[sub]2-VASc Scores Can Guide the Evaluation of Cryptogenic Ischemic Stroke

Author

Ekizoglu, Esme, Atmaca, Murat, Cinar-Balcioglu, Cagla, Yesilot, Nilufer, and Coban, Oguzhan

Subjects
Stroke (Disease) -- Diagnosis, Practice guidelines (Medicine), Diagnosis -- Usage, Neurology -- Usage, Health
Abstract

Byline: Esme. Ekizoglu, Murat. Atmaca, Cagla. Cinar-Balcioglu, Nilufer. Yesilot, Oguzhan. Coban Background and Aims: Cryptogenic ischemic strokes (CIS) are treated with antiplatelets for stroke prevention in routine clinical practice. The [...]

Published
2021

23. Gastrostomy in Hospitalized Patients with Acute Stroke: “NöroTek” Turkey Point Prevalence Study Subgroup Analysis

Author

Topçuoğlu, Mehmet Akif, primary, Özdemir, Atilla Özcan, additional, Aykaç, Özlem, additional, Milanoğlu, Aysel, additional, Gökçe, Mustafa, additional, Bavli, Songül, additional, Çabalar, Murat, additional, Yayla, Vildan, additional, Erdoğan, Hacı Ali, additional, Özkul, Ayça, additional, Güneş, Aygül, additional, Değirmenci, Bahar, additional, Aluçlu, Ufuk, additional, Kozak, Hasan Hüseyin, additional, Güngör, Levent, additional, Erdoğan, Mücahid, additional, Özdemir Acar, Zeynep, additional, Cenikli, Utku, additional, Kablan, Yüksel, additional, Yılmaz, Arda, additional, Genç, Hamit, additional, Nazliel, Bijen, additional, Batur Çağlayan, Hale, additional, Sarıönder Gencer, Elif, additional, Ay, Halil, additional, Demirbaş, Hayri, additional, Akdoğan, Özlem, additional, Emre, Ufuk, additional, Kayım Yıldız, Özlem, additional, Bolayır, Aslı, additional, Demir, Turgay, additional, Tanrıverdi, Zeynep, additional, Yalaz Tekan, Ülgen, additional, Akpınar, Çetin Kürşad, additional, Özkan, Esra, additional, İlik, Faik, additional, Şirin, Hadiye, additional, Güler, Ayşe, additional, Önder, Halil, additional, Bektaş, Hesna, additional, Öcek, Levent, additional, Bakar, Mustafa, additional, Ongun, Nedim, additional, Krespi, Yakup, additional, Togay Işıkay, Canan, additional, Aslanbaba, Eda, additional, Sorgun, Mine, additional, Gürkaş, Erdem, additional, Karadereli, Hasan Hüseyin, additional, Midi, İpek, additional, İlgezdi, İrem, additional, Bilgiç, Adnan Burak, additional, Akyol, Şener, additional, Epçeliden, M. Tuncay, additional, Atmaca, Murat Mert, additional, Kurşun, Oğuzhan, additional, Keskin, Onur, additional, Bekdik Şirinocak, Pınar, additional, Baydemir, Recep, additional, Akçakoyunlu, Merve, additional, Öztürk, Şerefnur, additional, Özel, Tuğba, additional, Ünal, Ali, additional, Dora, Babür, additional, Yürekli, Vedat Ali, additional, Arlıer, Zülfikar, additional, Eren, Alper, additional, Yılmaz, Ayşe, additional, Kısabay, Ayşin, additional, Acar, Bilgehan, additional, Baştan, Birgül, additional, Acar, Zeynep, additional, Niflioğlu, Buket, additional, Güven, Bülent, additional, Kaya, Dilaver, additional, Afşar, Nazire, additional, Yazıcı, Duran, additional, Aytaç, Emrah, additional, Yaka, Erdem, additional, Toplutaş, Eren, additional, Değirmenci, Eylem, additional, İnce, Fatma Birsen, additional, Büyükşerbetçi, Gülseren, additional, Aydın, İsa, additional, Çetiner, Mustafa, additional, Şen, Mustafa, additional, Turgut, Nilda, additional, Kale, Nilüfer, additional, Çoban, Eda, additional, Yeşilot, Nilüfer, additional, Ekizoğlu, Esme, additional, Kizek, Özgü, additional, Birgili, Özlem, additional, Yevgi, Recep, additional, Kunt, Refik, additional, Giray, Semih, additional, Yazıcı Akkaş, Sinem, additional, Şenadım, Songül, additional, Yoldaş, Tahir, additional, Asil, Talip, additional, Duman, Taşkın, additional, Atasoy, Tuğrul, additional, Piri Çınar, Bilge, additional, Demir, Tülin, additional, Can, Ufuk, additional, Özüm Ünsal, Yaprak, additional, Eşkut, Neslihan, additional, Aslan, Yıldız, additional, Baş, Demet Funda, additional, Şener, Ufuk, additional, Yılmaz, Zahide, additional, Bozdoğan, Zehra, additional, Alioğlu, Zekeriya, additional, and Arsava, Ethem Murat, additional

Published
2022
Full Text
View/download PDF

33. The significance of the morphology-voltage-P-wave duration (MVP) ECG score for prediction of in-hospital and long-term atrial fibrillation in ischemic stroke

Author

Hayıroğlu, Mert İlker, primary, Çınar, Tufan, additional, Selçuk, Murat, additional, Çinier, Göksel, additional, Alexander, Bryce, additional, Doğan, Selami, additional, Çiçek, Vedat, additional, Kılıç, Şahhan, additional, Atmaca, Murat Mert, additional, Orhan, Ahmet Lütfullah, additional, and Baranchuk, Adrian, additional

Published
2021
Full Text
View/download PDF

34. CHADS2 and CHA2DS2-VASc Scores Can Guide the Evaluation of Cryptogenic Ischemic Stroke.

Author

Ekizoglu, Esme, Atmaca, Murat, Cinar-Balcioglu, Cagla, Yesilot, Nilufer, Coban, Oguzhan, and Atmaca, Murat Mert

Abstract

Background and Aims: Cryptogenic ischemic strokes (CIS) are treated with antiplatelets for stroke prevention in routine clinical practice. The objective of this study was to investigate whether the CHADS2 and CHA2DS2-VASc scores may be used to identify the patients with CIS at higher risk of ischemic stroke despite antiplatelet therapy.Material and Methods: We calculated CHADS2 and CHA2DS2-VASc scores in patients with first ever CIS; those previously managed with antiplatelets (AP group) and in those without antiplatelets (non-AP group), using the prospectively recorded data of the Istanbul Medical School Stroke Registry from 1996-2014.Results: Of the 4466 IS patients, 886 patients with first ever IS had complete data for score calculation. Seventy-five (39 women) of them were diagnosed with CIS. CHADS2 and CHA2DS2-VASc scores were significantly higher in the AP group of 19 patients in comparison to the non-AP group of 56 patients (P = 0.005 and P = 0.009, respectively). ROC curve analyses showed an area under curve (AUC) of 0.705 (CI: 0.57-0.84; P = 0.008) for CHADS2 score ≥3 and AUC of 0.699 (CI: 0.57-0.82; P = 0.01) for CHA2DS2-VASc score ≥4. Vascular diseases were more frequent in the AP group and these patients were older than the patients in the non-AP group (P = 0.025, P = 0.024; respectively).Conclusions: CHA2DS2-VASc score ≥ 4 and CHADS2 score ≥3 may be used as a predictor of the occurrence of IS despite regular antiplatelet use and suggest an embolic source which will respond better to anticogulation. Our results support that CHADS2 and CHA2DS2-VASc scores may be useful to identify subgroups among patients with CIS for individualizing diagnostic approach, planning future workup and preventive treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. Acute Stroke Nursing: Standards and practical applications Turkish Society of Cerebrovascular Disease and the Society of Neurological Nursing: Joint Strategy Project

Author

Topcuoglu, Mehmet Akif, primary, Tulek, Zeliha, additional, Boyraz, Sakine, additional, Özdemir, Atilla Özcan, additional, Özakgül, Aylin, additional, Guler, Ayse, additional, Nazliel, Bijen, additional, Togay Isikay, Canan, additional, Yaka, Erdem, additional, Arsava, Ethem Murat, additional, Caglar, Gulsen, additional, Sirin, Hadiye, additional, Midi, Ipek, additional, Atmaca, Murat Mert, additional, Alankaya, Naile, additional, Ongun, Nedim, additional, Yıldırım, Nurdan, additional, Aykaç, Özlem, additional, Küçükgüçlü, Özlem, additional, and Usta Yeşilbalkan Ve Ark., Öznur, additional

Published
2020
Full Text
View/download PDF

49. The First Cure Experience of A Clinic: Approach to The Patient to Start Ocrelizumab.

Author

DEMİR, Serkan, ATMACA, Murat Mert, and TOGROL, Rıfat Erdem

Subjects
*MULTIPLE sclerosis, *DRUG efficacy, *MONOCLONAL antibodies, *RETROSPECTIVE studies, *LYMPHOPENIA, *DESCRIPTIVE statistics
Abstract

Introduction: Ocrelizumab is a newly introduced treatment in multiple sclerosis (MS). There is no data in the pivotal trials about in which extent liver function tests (LFTs) and lymphocyte count are affected before second-half dose of ocrelizumab and in which extent these results will prevent us giving the second-half dose. This study was designed for better understanding of the patient management and to support the data that showed no safety issues about ocrelizumab with real-life data. Methods: The patients treated with ocrelizumab between May 20 and December 21, 2018 were retrospectively reviewed. Demographic and clinical data, side-effects due to ocrelizumab, laboratory results before and after the treatment were recorded. Results: There were 30 (58.8%) females and 21 (41.2%) males. The mean age was 44.02±9.62 (24-65) years. Twenty-six (51%) of them were followed up with relapsing-remitting MS (RRMS), 18 (35.3%) with secondary progressive MS (SPMS) and 7 (13.7%) with primary progressive MS (PPMS). The mean lymphocyte value one day after the first half-dose was lower than the value before the treatment (p<0.001). The mean lymphocyte level one month after the second half-dose was higher than the value one day after the first half-dose (p=0.001), while it was still lower than the value before treatment (p=0.006). No changes were seen in LFTs. Mild infusion-related reactions were observed in 4 patients. Conclusion: From our data, it is evident that ocrelizumab is safe in the short term. Long-term real-life studies are needed to assess the safety of ocrelizumab in the long term. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

50. Lumbar Spinal Stenosis: A Rare Presentation of Hereditary Transthyretin Amyloidosis.

Author

ÇAKAR, Arman, ATMACA, Murat Mert, KOTAN, Dilcan, DURMUŞ, Hacer, DEYMEER, Feza, OFLAZER, Piraye, and PARMAN, Yeşim

Subjects
*AMYLOIDOSIS diagnosis, *GENETIC disorder diagnosis, *ELECTRODIAGNOSIS, *GENETIC mutation, *AMYLOIDOSIS, *ARTICULAR ligaments, *GENETIC disorders, *SPINAL stenosis, *SERUM albumin, *LEG, *MUSCLE weakness, *POLYNEUROPATHIES, *LARYNGEAL diseases, *LUMBAR vertebrae, *HISTOLOGY, *DEATH, *PHENOTYPES, *SYMPTOMS
Abstract

Hereditary transthyretin amyloidosis (hATTR) is caused by the mutations of the transthyretin (TTR) gene. Length dependent sensory-motor neuropathy with autonomic involvement is the hallmark of the disease. However, it can manifest with unusual phenotypes. A 53-year-old man presented with progressive weakness in lower limbs and operated for lumbar spinal stenosis. The progression of weakness restarted after two years with the addition of symptoms related to polyneuropathy. Electrodiagnostic studies revealed sensorimotor polyneuropathy with autonomic involvement. Sural nerve biopsy disclosed amyloid deposits. Genetic testing of TTR gene identified Glu89Gln mutation. Two years after the diagnosis, he had another decompressive surgery for lumbar spinal stenosis. Histopathological examination of ligamentum flavum specimens revealed amyloid deposits. During the follow up, he was diagnosed with laryngeal amyloidosis, which is an unusual manifestation. Seven years after the diagnosis, he died due to cardiac complications. Our patient suggested that hATTR with Glu89Gln may present with atypical symptoms. Clinicians should carefully look for hATTR in recurrent lumbar stenosis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results